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Lung cancer early detection by low-dose computed tomography (LDCT) can reduce the mortality. However, LDCT
increases the number of indeterminate pulmonary nodules (PNs), whereas 95% of the PNs are ultimately false
positives. Modalities for specifically distinguishing between malignant and benign PNs are urgently needed. We
previously identified a panel of peripheral blood mononucleated cell (PBMC)-miRNA (miRs-19b-3p and -29b-3p)
biomarkers for lung cancer. This study aimed to evaluate efficacy of integrating biomarkers and clinical and
radiological characteristics of smokers for differentiating malignant from benign PNs. We analyzed expression of 2
miRNAs (miRs-19b-3p and -29b-3p) in PBMCs of a training set of 137 individuals with PNs. We used multivariate
logistic regression analysis to develop a prediction model based on the biomarkers, radiographic features of PNs,
and clinical characteristics of smokers for identifying malignant PNs. The performance of the prediction model was
validated in a testing set of 111 subjects with PNs. A prediction model comprising the two biomarkers, spiculation
of PNs and smoking pack-year, was developed that had 0.91 area under the curve of the receiver operating
characteristic for distinguishing malignant from benign PNs. The prediction model yielded higher sensitivity
(80.3% vs 72.6%) and specificity (89.4% vs 81.9%) compared with the biomarkers used alone (all P b .05). The
performance of the prediction model for malignant PNs was confirmed in the validation set. We have for the first
time demonstrated that the integration of biomarkers and clinical and radiological characteristics could efficiently
identify lung cancer among indeterminate PNs.
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Lung cancer is the leading cancer killer in both men and women in the
United States. Tobacco smoking is the major cause of the disease.
Histologically, there are two major types of lung cancer: non–small cell
lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC
mainly comprises adenocarcinoma (AC), squamous cell carcinoma
(SCC), and large cell carcinoma (LCC). A National Cancer Institute
National Lung Screening Trial showed that the early detection of lung
cancer using low-dose computed tomography (LDCT) significantly
reduced the mortality [1]. LDCT is now used for lung cancer screening
in smokers [2]. Medicare pays for lung cancer screening with LDCT.
However, the CT scan has dramatically increased the number of
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To manage the indeterminate PNs, a workup consisting of noninvasive
and invasive techniques is proposed [3]. Noninvasive techniques include
follow-up with LDCT, positron emission tomography, or magnetic
resonance imaging for up to 2 years to confirm if it is a benign lesion.
These noninvasive techniques frequently lead to unnecessary procedures,
radiation exposure, anxiety, cost, and low accuracy for subjects with
benign lesions. Furthermore, observation with serial chest radiographs
may delay appropriate diagnosis and treatment when malignancy is really
existent. Invasive techniques comprise CT-guided transthoracic needle
and transbronchial biopsies. There is a risk of pneumothorax,
hemorrhage, and a false-negative result, which may lead to an
unacceptable therapeutic delay in early-stage lung cancer [4]. In the
end, a surgical procedure is often required to establish the final
diagnosis, which should be avoided in cases of benign growths.
The National Lung Screening Trial results also showed that 24.2%
of heavy smokers had indeterminate PNs detected by LDCT, whereas
96.4% of these PNs were ultimately confirmed as false positives [5].
CT screening trial yielded a sensitivity of more than 90% but a
specificity of 61% [1]. Therefore, LDCT screening for lung cancer in
heavy smokers may cause a high level of false-positive rate or
overdiagnosis [5]. Given the high false-positive rate of LDCT, there
will be an enormous number of referrals for the invasive and expensive
2-year multiple follow-up examinations that carry their own
morbidities and mortalities. Thus, it is clinically imperative to
develop new modalities that can accurately distinguish malignant
from benign PNs in a safe and cost-effective manner to prevent
individuals with benign growths from the biopsies and follow-up
examinations while allowing effective treatments to be immediately
initiated for lung cancer.
Analysis of biomarkers in body fluids may provide a safe and
cost-effective approach for diagnosing lung cancer. It has been
suggested that tumors could be recognized by the immune system and
that cancer cells can evade the elimination of immunological
surveillance [6]. Therefore, immune evasion might occur as an early
event in tumorigenesis [7,8]. Peripheral blood mononucleated cells
(PBMCs) mainly consist of monocytes, T cells, B cells, granulocytes,
and natural killer cells [9] and act as the first line of defense against
malignancy in the immune system [9]. Therefore, the determination
of molecular changes of PBMCs may open a surrogate window into
cancer status [8]. MicroRNAs (miRNAs) have important function in
the regulation of gene expression in various biological processes [10].
Alterations of miRNAs play crucial roles in tumorigenesis [10].
Furthermore, miRNAs are involved in the escaping events of cancer
cells from immunological surveillance [11]. Differential miRNA
expression patterns of PBMCs have been found in patients with
malignancies, suggesting that a PBMC-based miRNA profile could be
of use as cancer biomarkers [12,13]. We recently identify two PBMC
miRNA biomarkers (miRs-19b-3p and -29b-3p) that can diagnose
lung cancer with 72.6% sensitivity and 82.6% specificity [12].
However, the sensitivity and specificity of the biomarkers are not
sufficient to be used in clinical settings for differentiating between
malignant and benign PNs.
Previous studies have shown that predictive models based on
patient and PN variables could help discriminate lung cancer from
benign growths [14–18]. However, the diagnostic performance of the
prediction models also suffered from moderate sensitivity and
specificity for predicting malignant PNs [14–19]. Here we aimed
to investigate if combined analysis of the biomarkers, radiographicfeatures of PNs, and clinical characteristics of smokers could
efficiently identify lung cancer among the indeterminate PNs.
Materials and Methods
Patient Cohorts
This retrospective cohort study was approved by the Institutional
Review Boards of the University of Maryland Medical Center and the
Baltimore VAMedical Center. We consented the patients who visited
the Lung Nodule Clinic in the medical centers. Inclusion criteria were
current and former smokers who had LDCT-detected PNs and were
between the ages of 55 and 74 years. A PN was defined as a solitary,
round, or oval lesion in the lung parenchyma in the absence of
adenopathy, atelectasis, or pneumonia. Exclusion criteria included
age b 21 years, pregnancy or lactation, current pulmonary infection,
thoracic surgery within 6 months, radiotherapy to the chest within 1
year, and life expectancy of b1 year. We reviewed the medical records
for their demographic and clinical variables about age, gender, race,
ethnicity, history of cancer, and smoking behavior (smoking history,
smoking status, pack-years, and number of years since quitting).
Furthermore, radiographic characteristics of the PNs including the
maximum transverse size, the visually determined type (nonsolid or
with ground-glass opacity, part-solid or subsolid, or solid or
perifissural, spiculation), and the location in the lung were obtained.
The ground truth of a definitive malignant diagnosis was established
and verified based on pathologic examination of tissues obtained via
surgery or biopsy. Furthermore, a definitive benign diagnosis was
established when a specific benign etiology was confirmed pathologically
or if the PNs were clinically and radiographically stable (such as CT
imaging) after a 2-year follow-upwithmultiple examinations based on the
Fleischner Society guidelines [20]. The surgical pathologic staging was
determined according to the TNM classification of the International
Union Against Cancer with the American Joint Committee on Cancer
and the International Staging System for Lung Cancer. Histopathologic
classification was determined according to the World Health
Organization classification.
PBMC Preparation and Quantitative Reverse Transcriptase
Polymerase Chain Reaction (qRT-PCR) Analysis of miRNAs
We collected peripheral blood in BD Vacutainer spray-coated
K2EDTA Tubes (BD, Franklin Lakes, NJ) as described in our
previous report [12]. We isolated PBMCs by using Ficoll gradient
centrifugation [8]. We transferred PBMCs into RNAlater (Life
Technologies, Grand Island, NY). We extracted RNA by using the
Qiagen miRNeasy Mini Kit (Qiagen Inc., Valencia, CA) as described
in our previous study [8]. We performed qRT-PCR analysis of two
miRNAs (miRs-19b-3p and -29b-3p) as previously described [8].
Briefly, qRT-PCR was carried out on a CFX96 thermocycler
(Bio-Rad) at 95°C for 10 minutes followed by 40 cycles of 95°C
for 15 seconds and 60°C for 1 minutes. qPCR data were analyzed by
using the Manager software (Bio-Rad) with an automatic cycle
threshold (Ct) setting for assigning the baseline and threshold for Ct
determination. Relative expression of a targeted miRNA in a given
sample was computed using the equation 2 − ΔCt, where ΔCt = Ct
(targeted miRNA) − Ct (miR-423-3p), in which miR-423-3p was
used as an internal control for normalization of the target miRNAs
[12]. In our previous study [12], to identify an internal control for the
normalization of the miRNA qPCR data, we screened the expression
of all miRNAs represented in an analysis of array-based panel to find
the miRNAs with the minimal variation between lung cancer cases
Table 1. Characteristics of Patients with Malignant or Benign PNs in a Training Set
Characteristics Patients with Patients with
Malignant PNs (n = 68) Benign PNs (n = 69)
Clinical
Age 67.23 (SD 9.99) 66.25 (SD 8.12)
Sex
Male 45 46
Female 23 23
Race
African American 20 21
White 48 48
Smoking history
Current smoker 40 41
Former smoker 28 28
Pack-years 44.76 (SD 13.27) 23.69 (SD 12.46)
Years quit 13.26 (SD 8.98) 11.38 (SD 8.68)
History of cancer 8 2
Stage of non–small cell cancer
Stage I 18
Stage II 18
Stage III-VI 22
Histological type
AC 28
SCC 25
LC 5
SCLC 10
Radiological
Nodule size (mm) 20.39 (SD 11.27) 12.56 (SD 8.38)
Nodule location
Left lower lobe 9 14
Left upper lobe 25 18
Right lower lobe 15 19
Right middle lobe 4 6
Right upper lobe 15 9
Nodule type (number)
Nonsolid or ground-glass opacity 17 19
Perifissural 6 8
Part-solid 8 7
Solid 13 12
Spiculation 22 3
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control because its expression was very stable in all PBMC samples
with no significant difference between the groups determined by
normalizer. All assays were performed in triplicates.
Statistical Analysis
We used univariate and multivariate analyses to determine which
of the biomarkers and clinical and radiological variables were
associated with malignant PNs. The significantly associated factors
were then analyzed by using multivariate logistic regression models
with stepwise regression based on receiver-operator characteristic
(ROC) curve to select an optimal prediction model for malignant
PNs. The optimal cutoff value was generated using the Youden index.
The 95% confidence intervals in the ROC plot for proportions were
estimated. To compare the performance of the biomarkers only and
with added clinical/imaging variables, we used the method of Hanley
and McNeil [21]. The performance was evaluated by tabulating the
percentage of paired tests indicating a significant difference. We also
generated a 95% confidence interval for the difference in the area
under the ROCs (AUCs) by using the bootstrap [21]. The predictive
model developed in a training set of cohort was validated in a testing
set by comparing the calculated results with final clinical diagnosis
and the area under the AUC.
Results
The Clinical and Radiological Predictors for Malignant PNs
From December 1, 2011, to December 31, 2014, we enrolled 636
heavy smokers who had PNs. Among the subjects, 124 had malignant
PNs and 512 had benign PNs. Of the patients with malignant PNs,
108 were diagnosed with NSCLC, whereas 16 were diagnosed with
SCLC. The NSCLC patients consisted of 33 stage I, 34 stage II, and
41 stage III to IV cases. Of the NSCLC patients, 51 were diagnosed
to have AC, 47 have SCC, and 10 have LC. Of the 16 SCLC patients,
8 were diagnosed with limited stage, whereas 8 were diagnosed with
extensive stage. From the 512 cancer-free smokers, we randomly
selected 124 subjects with benign PNs as controls. The 248 patients
with either malignant or benign PNs were randomly split into a
training set and an internal testing set by using a validated random
number generator. The training set included 68 cancer cases and 69
cancer-free controls (Table 1) and was used for developing a
prediction model for malignant PNs. The testing set included 56
cancer cases and 55 cancer-free controls (Table 2) and was used for
the validation of the prediction model. Univariate analysis showed
that history of cancer and smoking pack-years were the clinical
predictors, whereas the diameter, spiculation, and upper lobe location of
the PNs were radiological predictors of malignant PNs (all P b .05)
(Table 3). Furthermore, multivariate analysis indicated that the
smoking pack-years of the subjects and the diameter and spiculation
of the PNs were predictors of malignant PNs (all P b .05) (Table 3).
A Prediction Model for Malignant PNs
The two PBMC miRNAs (miRs-19b-3p and -29b-3p) displayed a
significantly higher expression level in individuals with malignant
PNs compared with subjects with benign PNs (all P b .05).
Furthermore, the expression level of the PBMC miR-29b-3p was
correlated with the size of PNs (P = .02). The expression levels of
both miR-19b-3p and miR-29b-3p were associated with smoking
history of subjects (P = .01). In addition, the expression of the twomiRNAs was more associated with SCC compared with other
subtypes of lung cancer. Therefore, the two PBMCmiRNAs could be
also predictors of malignant PNs.
A Prediction Model Based on the Biomarkers, Radiographic
Features, andClinical Characteristics of Smokers forMalignant PNs
Because the two PBMC miRNAs; history of cancer and smoking
pack-years of the patients; and the diameter, spiculation, and upper
lobe location of the PNs were associated with malignant PNs, we used
multivariate logistic regression models with stepwise regression to
develop a prediction model for lung cancer. A prediction model was
developed: probability of malignant PNs = eU/(1 + eU), where e is
the base of the natural logarithm and U = −11.26+ 3.56 × log
(miRs-19b-3p) − 2.82 × log (miR29b-3p) + 0.18 × smoking
pack-years + 3.12 × spiculation of PN. Smoking pack-years =
(number of cigarettes smoked per day/20) × number of years smoked.
Spiculation = l if the edge of the PN has spicules (otherwise = 0). The
estimated AUC of the prediction model had 0.91 AUC in
distinguishing malignant from benign PNs, which was significantly
higher than that (0.81) of combined use of the two miRNA
biomarkers (Figure 1) (P = .02). The prediction model had 80.3%
sensitivity and 89.4% specificity for detection of malignant PNs,
which were also significantly higher compared with those (72.6%
sensitivity and 81.9% specificity) of the panel of the two biomarkers
(miRs-19b-3p and -29b-3p) (all P b .05) (Supplementary Table 1).
Table 2. Characteristics of Patients with Malignant or Benign PNs in a Testing Set
Characteristics Patients with Patients with
Malignant PNs (n = 56) Benign PNs (n = 55)
Clinical
Age 66.98 (SD 9.35) 65.29 (SD 8.32)
Sex
Male 37 36
Female 19 19
Race
African American 17 16
White 39 39
Smoking history
Current smoker 33 33
Former smoker 23 22
Pack-years 45.36 (SD 12.57) 24.23 (SD 11.56)
Years quit 13.46 (SD 8.36) 11.27 (SD 8.34)
History of cancer 6 2
Stage of non–small cell cancer
Stage I 15
Stage II 16
Stage III-VI 19
Histological type
AC 23
SCC 22
LC 5
SCLC 6
Radiological
Nodule size (mm) 20.48 (SD 11.57) 12.36 (SD 8.48)
Nodule location
Left lower lobe 7 11
Left upper lobe 21 15
Right lower lobe 12 15
Right middle lobe 3 5
Right upper lobe 12 7
Nodule type (number) 0
Nonsolid or ground-glass opacity 16 17
Perifissural 7 8
Part-solid 7 6
Solid 6 5
Spiculation 18 2
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(94.8% vs 89.4%, P = .03) for the detection of SCC compared with
the diagnosis of all types of lung cancer while maintaining a similar
sensitivity (80.4% vs 80.3%, P = .46) (Supplementary Table 2). The
prediction model did not exhibit statistical differences of sensitivity
and specificity between stages of lung cancer (P N .05).
Validating the Prediction Model for Differentiating Malignant
from Benign PNs in a Testing Cohort
The molecular and clinical data and radiographic features of PNs in
the validation set were used to test the performance of the model by
comparing the calculated results with final clinical diagnosis and theTable 3. Univariate and Multivariate Analyses of Potential Predictors of Malignant PNs
A Training Set A Testing Set
Variable OR 95% CI P OR 95% CI P
Univariate analysis
Smoking pack-year 1.22 1.01-1.26 .002 1.26 1.19-1.32 .003
History of cancer 1.35 1.30-1.40 .021 1.34 1.28-1.43 .023
Nodule size 1.16 1.12-1.22 .001 1.17 1.11-1.22 .010
Nodule Location 2.79 2.70-3.16 .036 2.66 2.56-3.15 .020
Spiculation 5.76 5.62-6.23 b.001 5.68 5.59-6.58 b.001
Multivariate analysis
Smoking pack-year 1.26 1.12-1.30 .001 1.29 1.22-1.36 .006
Nodule size 2.23 1.88-2.86 .022 2.46 1.75-2.87 .020
Spiculation 2.68 2.03-3.69 .002 2.95 2.12-3.99 .001AUC value. The prediction model created an AUC of 0.91
(Supplementary Table 3), suggesting its reproducibility in distin-
guishing between benign and malignant PNs. Furthermore, the
prediction model had 80.4% sensitivity and 89.1% specificity for the
identification of malignant PNs. In addition, the prediction model
had higher sensitivity and specificity for detection of malignant PNs
compared with the biomarkers (80.4% vs 73.2%, 89.1% vs 81.2%,
all P b .05) (Supplementary Table 3). Moreover, the prediction
model had a higher specificity (94.6% vs 89.1%, P = .03) for the
detection of SCC compared with all types of lung cancer while
maintaining a similar sensitivity (81. 8% vs 80. 4%, P = .39)
(Supplementary Table 2). The results generated from the testing
cohort confirmed the potential of using the prediction model as an
assay for distinguishing malignant from benign PNs.
Discussion
Each year, about 2.6 million subjects in the United States will be
screened by using LDCT [22]. More than 700,000 heavy smokers
will have a positive diagnosis without a clear indication of cancer [22].
Therefore, precisely identifying lung cancer in the subjects with
indeterminate PNs is a primary medical concern. In a retrospective
cohort of 629 patients with PNs, Swensen et al. identified 6
independent predictors of malignancy: older age, a history of
smoking, a history of an extrathoracic cancer more than 5 years
before nodule detection, larger nodule diameter, upper lobe location,
and spiculated margins [14]. A prediction model was developed using
the six predictors that had 0.83 AUC in the identification of the
malignancy in radiologically indeterminate PNs. Furthermore, in a
retrospective cohort of 375 veterans with PNs, Gould et al. derived
another model including older age, a history of smoking, larger
nodule diameter, and shorter time since quitting smoking, producing
0.78 AUC for estimating the clinical probability of lung cancer in
patients with PNs [15,16]. In addition, using data from two separate
LDCT screening cohorts, McWilliams et al. recently developed
prediction models that could estimate the probability of lung nodules
that might be malignant ones [17]. Although the clinical and
radiological characteristics-based models show promising, the
sensitivity and specificity need to be improved for lung cancer
detection in PNs.
Our present study confirms the previous findings that the clinical
and radiological variables could be predictors for malignant PNs,
including the history of cancer; smoking pack-years of the subjects;
and the diameter, spiculation, and upper lobe location of the PNs.
Furthermore, this study validates the diagnostic values of our
previously identified PBMC-miRNA biomarkers for lung cancer
[12]. Importantly, from the heterogeneous predictors, using logistic
regression models with stepwise regression, we optimize a new
prediction model for distinguishing malignant from benign PNs. This
parsimonious model comprises two biomarkers, one radiological
variable of PNs, and one clinical factor of smokers. The prediction
model produced higher sensitivity and specificity for prediction of
malignant PNs compared with the biomarkers used alone. In
addition, the performance of this model could identify SCC with a
higher specificity compared with other types of lung cancer while
keeping a similar sensitivity. Given that radiographic imaging has
limited capability to differentiate between benign and malignant
lesions, particularly centrally located SCCs [1,23], future use of the
prediction model would help make decisions about the management
of CT-detected abnormalities of undetermined importance.
Figure 1. ROC curve analysis of a prediction model and a panel of two PBMC miRNA biomarkers (miRs-19b-3p and -29b-3p) for
distinguishing between malignant and benign PNs in a training set of patients. The AUC for each approach conveys its accuracy for
diagnosis of malignant PNs. The predictionmodel produces a higher AUC value for identifyingmalignant PNs (A) compared with the panel
of the two PBMC miRNA biomarkers (B) (P = .02).
44 A prediction model for lung cancer Ma et al. Translational Oncology Vol. 10, No. xx, 2016The study has some limitations. 1) Based on the Food and Drug
Administration criteria [24], any screening test directed at a disease
with a prevalence of 5% or less must detect preclinical disease with a
sensitivity exceeding 95% when the specificity is less than or equal to
95%, and vice versa [24]. The prevalence of lung cancer in high-risk
groups is at 1% to 3%, whereas LDCT has about 90% sensitivity and
61% specificity for lung cancer early detection. Ideal prediction
modalities should have 95% sensitivity and 95% specificity for
predicting malignant PNs and thus augment the performance of CT
for targeted screening for lung cancer. However, the prediction
model, although promising, does not possess the required diagnostic
performance (95% sensitivity and 95% specificity) for routine clinical
application. In the future, we should identify additional biomarkers
and clinical and radiological characteristics that can be added to the
current prediction model so that the diagnostic efficacy of the
approach could be improved. 2) The sample size is small.
Furthermore, cases and controls used in this study were recruited
from the hospital-based patients with PNs. The prevalence of lung
cancer in the hospital-based population with PNs was 19.5%. The
subjects might not be representative of the individuals in LDCT
screening setting for lung cancer. We will perform a prospective trial
to determine if the analysis of the prediction model could be an
effective high-throughput screening for specifically identifying
NSCLC in a large population-based LDCT screening positive setting
among heavy smokers.
Conclusion
We have for the first time developed a parsimonious prediction model
by integrating biomarkers and clinical and radiological characteristics
of smokers that could identify lung cancer among indeterminate PNs.
Future use of the prediction model would have the following
important benefits [14]: 1) surgery for early-stage lung cancer could
immediately be expedited without the risk of the tumor metastasizing
during a long follow-up duration; 2) invasive and expensive
bronchoscopy and transthoracic needle aspiration biopsy procedures
could be used more appropriately; 3) multiple and expensive
noninvasive techniques that might lead to unnecessary procedures,
radiation exposure, anxiety, cost, and low accuracy for subjects with
benign lesions could be avoided; and 4) the expense and risk ofsurgery for benign PNs could be reduced. Nonetheless, undertaking
external and prospective validation study of the prediction model for
lung cancer is required.
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